These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29683099)

  • 41. The Effects of Annatto Tocotrienol on Bone Biomechanical Strength and Bone Calcium Content in an Animal Model of Osteoporosis Due to Testosterone Deficiency.
    Chin KY; Gengatharan D; Mohd Nasru FS; Khairussam RA; Ern SL; Aminuddin SA; Ima-Nirwana S
    Nutrients; 2016 Dec; 8(12):. PubMed ID: 27983628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Effects of Tocotrienol and Lovastatin Co-Supplementation on Bone Dynamic Histomorphometry and Bone Morphogenetic Protein-2 Expression in Rats with Estrogen Deficiency.
    Chin KY; Abdul-Majeed S; Mohamed N; Ima-Nirwana S
    Nutrients; 2017 Feb; 9(2):. PubMed ID: 28212283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mevalonate Pathway and Human Cancers.
    Bathaie SZ; Ashrafi M; Azizian M; Tamanoi F
    Curr Mol Pharmacol; 2017; 10(2):77-85. PubMed ID: 26758953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The mevalonate pathway: importance in mesangial cell biology and glomerular disease.
    O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
    Miner Electrolyte Metab; 1993; 19(3):173-9. PubMed ID: 8232104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mevalonate-suppressive dietary isoprenoids for bone health.
    Mo H; Yeganehjoo H; Shah A; Mo WK; Soelaiman IN; Shen CL
    J Nutr Biochem; 2012 Dec; 23(12):1543-51. PubMed ID: 22981371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Traditional Chinese medicine formulas for the treatment of osteoporosis: Implication for antiosteoporotic drug discovery.
    Zhang ND; Han T; Huang BK; Rahman K; Jiang YP; Xu HT; Qin LP; Xin HL; Zhang QY; Li YM
    J Ethnopharmacol; 2016 Aug; 189():61-80. PubMed ID: 27180315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peroxisome proliferator-activated receptor γ down-regulation mediates the inhibitory effect of d-δ-tocotrienol on the differentiation of murine 3T3-F442A preadipocytes.
    Torabi S; Yeganehjoo H; Shen CL; Mo H
    Nutr Res; 2016 Dec; 36(12):1345-1352. PubMed ID: 27884413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Introduction to bisphosphonates. History and functional mechanisms].
    Fleisch H
    Orthopade; 2007 Feb; 36(2):103-4, 106-9. PubMed ID: 17277961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of dynamin-2-mediated endocytosis as a new target of osteoporosis drugs, bisphosphonates.
    Masaike Y; Takagi T; Hirota M; Yamada J; Ishihara S; Yung TM; Inoue T; Sawa C; Sagara H; Sakamoto S; Kabe Y; Takahashi Y; Yamaguchi Y; Handa H
    Mol Pharmacol; 2010 Feb; 77(2):262-9. PubMed ID: 19903825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S; Kamiya S; Ono K
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss of HMG-CoA reductase in C. elegans causes defects in protein prenylation and muscle mitochondria.
    Ranji P; Rauthan M; Pitot C; Pilon M
    PLoS One; 2014; 9(2):e100033. PubMed ID: 24918786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
    Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevalonate.
    Straka MS; Panini SR
    Arch Biochem Biophys; 1995 Feb; 317(1):235-43. PubMed ID: 7872789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mitogenic effect of lithium in FRTL-5 cells can be reversed by blocking de novo cholesterol synthesis and subsequent signal transduction.
    Tasevski V; Benn D; King M; Luttrell B; Simpson A
    Thyroid; 2000 Apr; 10(4):305-11. PubMed ID: 10807058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Linköping University Medical Dissertation No. 1033. Following the mevalonate pathway to bone heal alley.
    Skoglund B
    Acta Orthop Suppl; 2007 Dec; 78(328):3-22. PubMed ID: 18283564
    [No Abstract]   [Full Text] [Related]  

  • 58. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
    Thurnher M; Nussbaumer O; Gruenbacher G
    Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages.
    Munoz MA; Fletcher EK; Skinner OP; Jurczyluk J; Kristianto E; Hodson MP; Sun S; Ebetino FH; Croucher DR; Hansbro PM; Center JR; Rogers MJ
    Elife; 2021 Dec; 10():. PubMed ID: 34967731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.